Merus Licenses US Commercialization Rights For Cancer Potential Zenocutuzumab, Analyst Highlight Merus' Pipeline
Merus N.V. (NASDAQ:MRUS) and Partner Therapeutics Inc, a private biotechnology company focused on hematology and oncology, ...
Biocon Biologics gets US nod to launch Stelara biosimilar
Biocon Biologics has secured USFDA approval to launch the biosimilar of Janssen's Stelara by February 2025, targeting ...
Yahoo Finance10d
U.S. FDA Approves StemCyte Biologics License Application for REGENECYTE™ Cord Blood Cell Therapy Product
Nov. 22, 2024 /PRNewswire/ -- StemCyte Inc., a wholly owned subsidiary of StemCyte International Ltd., announced today that ...
Targeted Oncology6h
November 2024 FDA Updates: Key Developments in Oncology
The FDA granted approval to nilotinib (Danziten) on November 14, 2024, for the treatment of adult patients with newly ...
oncnursingnews8d
Accelerated Approval Sought for RP1-Nivolumab Combo for Pretreated Melanoma
The FDA received a biologics license application for accelerated approval of RP1 plus nivolumab for advanced, pretreated ...
Replimune: RPL1 BLA Submission Under AA Pathway Makes It A Must Watch
Replimune's BLA submission and promising pipeline drugs are set to impact the global melanoma therapeutics market. Read more ...
Merus, Partner Therapeutics Ink Deal To Commercialize Zenocutuzumab In US, Stock Up In Pre-Market
Monday announced an agreement with Partner Therapeutics, Inc. to commercialize Zenocutuzumab for the treatment of ...
Merus, Partner Therapeutics enter agreement for Zenocutuzumab commercialization
N.V. and Partner Therapeutics, Inc., a private, fully-integrated biotechnology company with a focus in hematology and oncology, announced they have entered into an agreement in which Merus has ...
Targeted Oncology6d
FDA Receives BLA for RP1 and Nivolumab Combo in Advanced Melanoma
The FDA has received a biologics license application submission for RP1 plus nivolumab in patients with PD-1 ...
Replimune Group (NASDAQ: REPL) Submits Biologics License Application for RP1 in Combination with Nivolumab to FDA
On November 21, 2024, Replimune Group, Inc. (NASDAQ: REPL) made significant strides in the advancement of its lead product candidate, RP1. The company announced the submission of a biologics license ...
The Victoria Advocate10d
U.S. FDA Approves StemCyte Biologics License Application for REGENECYTE™ Cord Blood Cell Therapy Product
has approved the Biologics License Application (BLA) for its HPC, Cord Blood product REGENECYTE™, a vital cord blood stem cell therapy for transplantation in patients with blood and immune ...